A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder

@article{Ghanizadeh2015ASR,
  title={A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder},
  author={Ahmad Ghanizadeh},
  journal={Nordic Journal of Psychiatry},
  year={2015},
  volume={69},
  pages={241 - 248}
}
  • A. Ghanizadeh
  • Published 12 May 2015
  • Medicine, Psychology
  • Nordic Journal of Psychiatry
Abstract Background: No published systematic review has ever assessed the efficacy and safety of reboxetine for treating of patients with attention deficit hyperactivity disorder (ADHD). Aim: This systematic review aimed to review the available evidence regarding the efficacy of reboxetine for treating ADHD. Method: The databases of Pubmed/Medline, Google scholar, SCOPUS and Web of Science were searched using the Keywords: “reboxetine”, “ADHD” and “attention deficit hyperactivity disorder”. The… 
Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review
TLDR
While available evidence addressed mainly the efficacy and tolerability of psychostimulants and non-psychostimULants for ADHD core symptoms in the short term, further empirical support is needed for the non-pharmacological and multimodal treatments.
Management of anxiety disorders in children with attention-deficit hyperactivity disorder: a narrative review
TLDR
Adjunctive cognitive-behavior therapy for anxiety disorder symptoms is strongly recommended and is considered superior to medication alone, and in moderate and severe cases of comorbid Ads, selective serotonin reuptake inhibitors can be added to the stimulants, with the required caution.
Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis
TLDR
Network meta-analysis offered a broader overview on the available treatments for ADHD, especially for safety issues, and contributes towards evidence gathering and clinical practice decisions.
Development of the Korean Practice Parameter for Adult Attention-Deficit/Hyperactivity Disorder
  • G. BahnYoung Sik Lee Y. Joung
  • Psychology, Medicine
    Soa--ch'ongsonyon chongsin uihak = Journal of child & adolescent psychiatry
  • 2020
TLDR
The Korean practice parameter introduces not only general information for the diagnosis and treatment of adult ADHD on a global scale, but also the process of diagnosis and Treatment options tailored to the Korean population.
The Treatment of Adult ADHD: Complexity at Hand
TLDR
In order to provide specific and targeted interventions, it should be mandatory to address all dimensions (i.e., inattention, impulsivity, hyperactivity, emotional dysregulation) that appeared most affected when the patient asked for help.
Predictive validity of the neurokinin-1 knockout mouse in research into Attention Deficit Hyperactivity Disorder
TLDR
Three studies consolidate the predictive validity of the NK1R-/- mouse model of ADHD, highlight a role for NK1Rs in growth and body composition, and consolidate the effects of ADHD treatments on ADHD-like behaviour.
*Please see amendment for Pennsylvania Medicaid at the end of this CPB. I. Aetna considers certain services medically necessary for the assessment of attention deficit hyperactivity disorder (ADHD): Complete psychiatric evaluation (adults) Electroencephalography (EEG) or neurological consult when th
  • Medicine, Psychology
  • 2017
Complete psychiatric evaluation (adults) Electroencephalography (EEG) or neurological consult when the presence of focal signs or clinical findings are suggestive of a seizure disorder or a
TREATMENT
TLDR
It is shown that the pressutrc of the cecrebrospinal fluti can be altered very rapidly aid very definitelv by intraveniouis injectiolns of soluitionis of various conicentratioiis.
...
...

References

SHOWING 1-10 OF 48 REFERENCES
Atomoxetine for Treating ADHD Symptoms in Autism
  • A. Ghanizadeh
  • Medicine, Psychology
    Journal of attention disorders
  • 2013
TLDR
There are not enough controlled clinical trials for showing the efficacy of atomoxetine for treatment of ADHD symptoms in autism and there is no evidence that it is effective in high-functioning patients with autism or patients with low severity.
An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder.
TLDR
This open-label study suggests the efficacy of reboxetine in the treatment of ADHD in children and adolescents, and controlled studies in larger samples are needed.
SIX WEEK OPEN-LABEL REBOXETINE TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
TLDR
The results of the current study suggest the effectiveness of reboxetine in the treatment of ADHD in children and adolescents, and double-blind, placebo-controlled studies and larger sample size with long duration of intervention are indicated.
Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder
TLDR
It is revealed that reboxetine may be beneficial in treatment of ADHD and further studies are required to clarify the potential therapeutic effects on comorbid depression and anxiety and adverse effect profile.
A comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit-Hyperactivity Disorder (ADHD)
TLDR
Results of this study showed that reboxetine did not affect the RT of the patients when both visual and auditory tasks were assessed and further studies with larger number of patients and for a longer period of time are required.
Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study
TLDR
The initial findings of the study show that reboxetine may constitute an effective tool for long-term treatment of children with ADHD who present poor response or poor tolerance to initial treatment with methylphenidate.
Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: a long-term follow-up study.
TLDR
The results suggest the long-term effectiveness and safety of reboxetine maintenance treatment in children with ADHD is suggested and future large-scale, long- term, placebo/comparator-controlled studies should assess the benefit/risk ratio of rebboxetine in ADHD children.
Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.
TLDR
The results of the current open-label study suggest the effectiveness of reboxetine in the treatment of ADHD in methylphenidate-resistant children and adolescents is suggested.
A Possible Antienuretic Effect of Reboxetine in Children and Adolescents with Attention Deficit/Hyperactivity Disorder: Case Series
TLDR
Six children with primary nocturnal enuresis and with attention deficit/hyperactivity disorder with or without other comorbid disorders were treated with reboxetine and a statistically significant decrease in bedwetting was noted along the assessment points.
Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial.
TLDR
The findings suggest that reboxetine may be effective in the treatment of HCD and associated symptoms.
...
...